{"id":881624,"date":"2025-09-03T14:00:11","date_gmt":"2025-09-03T18:00:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-breaks-ground-on-new-manufacturing-hub-a-cornerstone-of-its-u-s-growth-and-innovation-strategy\/"},"modified":"2025-09-03T14:00:11","modified_gmt":"2025-09-03T18:00:11","slug":"gilead-sciences-breaks-ground-on-new-manufacturing-hub-a-cornerstone-of-its-u-s-growth-and-innovation-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gilead-sciences-breaks-ground-on-new-manufacturing-hub-a-cornerstone-of-its-u-s-growth-and-innovation-strategy\/","title":{"rendered":"Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy"},"content":{"rendered":"

<\/p>\n

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy<\/b><\/p>\n

New Bay Area Building Marks Significant Progress as Part of $32 Billion U.S. Investment Projected to Create $43 Billion in Economic Value<\/i><\/p>\n

FOSTER CITY, Calif.–(BUSINESS WIRE<\/a>)–
\nGilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company\u2019s Foster City headquarters. This milestone marks continued momentum in Gilead\u2019s multi-year strategy<\/a> to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead\u2019s planned $32 billion investment in U.S. innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America\u2019s biopharmaceutical leadership while fueling high-quality jobs, research, and domestic manufacturing.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20250903363682\/en\/<\/a><\/p>\n

\"Gilead<\/p>\n

Gilead Sciences breaks ground on new manufacturing and technical development site in Bay Area.<\/p>\n<\/div>\n

\n\u201cThis new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead\u2019s $32 billion investment commitment in the United States,\u201d said Daniel O\u2019Day, Chairman and Chief Executive Officer of Gilead Sciences. \u201cWe have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation.\u201d<\/p>\n

\nThe five-story, 180,000 square foot facility will serve as a hub for innovation and collaboration across technical development and manufacturing teams. Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead\u2019s pipeline. It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharma industry.<\/p>\n

\nThe new facility will strengthen Gilead\u2019s biologics capacity and capabilities, a central pillar of the company\u2019s growth strategy. This investment builds on Gilead\u2019s broader U.S. efforts to expand research and manufacturing, create more than 3,000 direct and indirect high-quality jobs, and advance equitable access to healthcare nationwide.<\/p>\n

\n\u201cCalifornia is proud to be home to Gilead Sciences and its ongoing investment in innovation and jobs right here in Foster City,\u201d said California Lieutenant Governor Eleni Kounalakis. \u201cThis new Technical Development Center is more than a milestone for Gilead; it\u2019s a win for all who will benefit from its breakthroughs. It demonstrates that when we invest in domestic biomanufacturing, we strengthen supply chains, create thousands of good-paying jobs, and keep America at the forefront of life-saving innovation.\u201d<\/p>\n

\nThis groundbreaking is part of a broader expansion at Gilead\u2019s Foster City headquarters. In addition to the NTDC, the company is currently developing two other state-of-the-art facilities: a new research building designed to accelerate scientific discovery, already under construction, and a biologics manufacturing facility that will expand domestic production capacity. These current investments further build on Gilead\u2019s strong history of U.S. investment, with more than $15 billion over the last decade, and reinforce the company\u2019s role as a major contributor to the U.S. biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for patients. Together, these investments form an integrated innovation ecosystem designed to accelerate discovery, streamline manufacturing, and reinforce Gilead\u2019s role as a U.S.-based biopharma leader in improving human health globally.<\/p>\n

\nToday\u2019s event features remarks from Gilead leadership including Daniel O\u2019Day, CEO, Stacey Ma, Executive Vice President, Pharmaceutical Development and Manufacturing, and Joydeep Ganguly, Senior Vice President, Corporate Operations. Distinguished guests include:<\/p>\n